[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Invited Commentary
Pharmacy and Clinical Pharmacology
November 27, 2019

Further Evidence to Monitor Long-term Proton Pump Inhibitor Use

Author Affiliations
  • 1Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
  • 2School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada
  • 3Women’s College Hospital, Toronto, Ontario, Canada
  • 4Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada
JAMA Netw Open. 2019;2(11):e1916184. doi:10.1001/jamanetworkopen.2019.16184

Proton pump inhibitors (PPIs) are antiacid secretory agents that are first-line therapy for gastroesophageal reflux disease, peptic ulcer disease, and a wide range of other gastrointestinal disorders.1 Proton pump inhibitors are among the most commonly dispensed drug classes in the United States; omeprazole alone was dispensed more than 70 million times in 2016,2 and 1 in 10 of all patients with ambulatory care visits in the United States in 2009 had documented PPI use.3 In addition, over-the-counter formulations of PPIs have been available since 2003 for the short-term treatment of frequent heartburn. Although PPIs are effective and necessary long-term therapies for certain rare conditions, such as Zollinger-Ellison syndrome, most common indications for PPIs, such as gastroesophageal reflux disease, require only short-term use of the drugs and little evidence supports their long-term use.1 However, unnecessary off-label long-term use of PPIs is prevalent, with up to 65% of patients receiving PPI therapy in the United States having no documented ongoing indication,4 raising concerns about inappropriate polypharmacy and its risks.1 Although PPIs are considered safe overall, they have now been linked to numerous adverse events, including drug-drug interactions, hypomagnesemia, osteoporotic fractures, and serious infections.1 The study by Vilcu and colleagues5 investigates an emerging concern of infectious complications associated with persistent PPI use: increased risk of acute gastroenteritis (AGE) during AGE epidemics.

The objective of the study by Vilcu and colleagues5 was to measure the association between continuous PPI therapy and the occurrence of AGE using a large French community-pharmacy drug dispensation database. The authors used a retrospective matched cohort design to estimate the association between PPI use and AGE incidence during an AGE epidemic period (the 5 weeks of peak AGE incidence in the winter of 2015 to 2016) among patients with at least 1 PPI prescription in the 100 days before and 100 days after the epidemic period. Incident AGE was defined using a drug dispensing algorithm previously found to correlate with an indicator for AGE in French general practitioner records.6

Vilcu and colleagues5 found a significant association between PPI use and AGE (relative risk, 1.81; 95% CI, 1.72-1.90), translating to a number needed to harm of 153 patients. Of note, the authors also found a significant association between AGE and histamine 2 receptor antagonists in a sensitivity analysis (adjusted relative risk, 2.08; 95% CI, 1.27-3.39). A significant association between PPI use and age was found, with older age groups (aged 45-64 years) at highest risk and younger age groups (aged 0-14 years and 15-44 years) at no significant increased risk. Vilcu et al5 concluded that continuous exposure to PPIs was associated with an increased risk of AGE during epidemic periods. Acute gastroenteritis was identified by the authors as another potential adverse effect of PPI therapy that possibly is more prevalent among older patients than younger ones. This risk is supported by the biological mechanism that PPIs may promote overgrowth of gut flora.5 These results align with those of previous studies7,8 that identified associations between PPI use and incidence of specific enteric illnesses, including those caused by Clostridium difficile and norovirus (a prominent pathogen associated with AGE).5

Although Vilcu et al5 thoroughly address limitations of their study, including outcome ascertainment using drug dispensing data and confounding by indication, it is important to reiterate that the possibilities of residual confounding and protopathic bias remain, particularly because adjustment for comorbidities relied on drug dispensation information alone. In the study, as is common in many settings, patients receiving long-term PPI treatment were significantly sicker than non–PPI users. These patients may have a higher baseline risk of viral exposure and susceptibility to AGE due to excess frailty, compromised immunity, or increased contact with the health care system. The results are certainly intriguing and should be replicated.

Regardless of limitations, the study by Vilcu et al5 highlights a new potential risk of PPI therapy and offers important takeaway points related to the large number of higher-risk patients using PPIs and whether long-term therapy is indicated. Importantly, these results add to a growing body of literature supporting the importance of deprescribing of PPIs to reduce potential adverse effects. Deprescribing guidelines have been published to guide clinicians in stopping or dose-reducing inappropriate PPI therapy,1 particularly among those with no present, identifiable indication for the drug. Discontinuation of inappropriate PPI therapy in older adults (aged ≥65 years) is also a component of the STOPP/START criteria9 and Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.10 In addition to medical record reviews to discontinue inappropriately prescribed PPI therapy, clinicians should also ask patients about over-the-counter medication use to comprehensively screen for PPI deprescribing opportunities. Indications for long-term PPI therapy in ambulatory patients should be limited to prevention of nonsteroidal anti-inflammatory drug–induced ulcers, severe esophagitis, Barrett esophagus, idiopathic chronic ulcer, refractory gastroesophageal reflux disease, pathologic hypersecretory conditions (eg, Zollinger-Ellison syndrome), and certain patients with a history of gastrointestinal ulcer with bleeding.1 Potential candidates for deprescribing include patients with a history of Helicobacter pylori infection, peptic ulcer disease, heartburn, dyspepsia, or gastroesophageal reflux disease but no present indication for antisecretory treatment.1 In addition, an overall evaluation of the need for any acid-reducing therapy should be considered first, rather than simply switching from PPIs to histamine 2 receptor antagonist therapy, given that both PPIs and histamine 2 receptor antagonists were associated with AGE incidence in the study by Vilcu et al.5

The study by Vilcu et al5 flags yet another potential risk of therapy with what was previously thought to be a generally safe drug class. Asking patients about all medication use, including over-the-counter drugs, and understanding why a patient is using a PPI are imperative to identifying deprescribing needs and reducing adverse drug effects. For patients with a documented indication for PPI use, clinicians should ensure that the expected benefits are balanced against the risks of PPI therapy and that the lowest effective dose be used for the shortest recommended duration.

Back to top
Article Information

Published: November 27, 2019. doi:10.1001/jamanetworkopen.2019.16184

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Hayes KN et al. JAMA Network Open.

Corresponding Author: Mina Tadrous, PharmD, MS, PhD, Women’s College Hospital, 76 Grenville St, Toronto, ON M5V 3C9, Canada (mina.tadrous@wchospital.ca).

Conflict of Interest Disclosures: Dr Nakhla reported receiving personal fees from Pfizer outside the submitted work. No other disclosures were reported.

References
1.
Farrell  B, Pottie  K, Thompson  W,  et al.  Deprescribing proton pump inhibitors: evidence-based clinical practice guideline.  Can Fam Physician. 2017;63(5):354-364.PubMedGoogle Scholar
2.
Agency for Healthcare Research and Quality. MEPS summary tables: prescribed drugs. https://meps.ahrq.gov/mepstrends/hc_pmed/. Published 2016. Accessed September 25, 2019.
3.
Rotman  SR, Bishop  TF.  Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009.  PLoS One. 2013;8(2):e56060. doi:10.1371/journal.pone.0056060PubMedGoogle Scholar
4.
Nardino  RJ, Vender  RJ, Herbert  PN.  Overuse of acid-suppressive therapy in hospitalized patients.  Am J Gastroenterol. 2000;95(11):3118-3122.PubMedGoogle Scholar
5.
Vilcu  AM, Sabatte  L, Blanchon  T,  et al.  Association between acute gastroenteritis and continuous use of proton pump inhibitors during winter periods of highest circulation of enteric viruses.  JAMA Netw Open. 2019;2(11):e1916205. doi:10.1001/jamanetworkopen.2019.16205Google Scholar
6.
Vilcu  AM, Blanchon  T, Sabatte  L,  et al.  Cross-validation of an algorithm detecting acute gastroenteritis episodes from prescribed drug dispensing data in France: comparison with clinical data reported in a primary care surveillance system, winter seasons 2014/15 to 2016/17.  BMC Med Res Methodol. 2019;19(1):110. doi:10.1186/s12874-019-0745-5PubMedGoogle ScholarCrossref
7.
Prag  C, Prag  M, Fredlund  H.  Proton pump inhibitors as a risk factor for norovirus infection.  Epidemiol Infect. 2017;145(8):1617-1623. doi:10.1017/S0950268817000528PubMedGoogle ScholarCrossref
8.
Imhann  F, Bonder  MJ, Vich Vila  A,  et al.  Proton pump inhibitors affect the gut microbiome.  Gut. 2016;65(5):740-748. doi:10.1136/gutjnl-2015-310376PubMedGoogle ScholarCrossref
9.
O’Mahony  D, O’Sullivan  D, Byrne  S, O’Connor  MN, Ryan  C, Gallagher  P.  STOPP/START criteria for potentially inappropriate prescribing in older people: version 2.  Age Ageing. 2015;44(2):213-218. doi:10.1093/ageing/afu145PubMedGoogle ScholarCrossref
10.
2019 American Geriatrics Society Beers Criteria® Update Expert Panel.  American Geriatrics Society 2019 updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults.  J Am Geriatr Soc. 2019;67(4):674-694. doi:10.1111/jgs.15767PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×